Buprenorphin "Actavis" 2 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

buprenorphin "actavis" 2 mg resoribletter, sublinguale

actavis group ptc ehf. - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg

Buprenorphin "Actavis" 8 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

buprenorphin "actavis" 8 mg resoribletter, sublinguale

actavis group ptc ehf. - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg

Buprenorphine "Orifarm" 2 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

buprenorphine "orifarm" 2 mg resoribletter, sublinguale

orifarm generics a/s - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg

Buprenorphine "Orifarm" 8 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

buprenorphine "orifarm" 8 mg resoribletter, sublinguale

orifarm generics a/s - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg

Subutex 2 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

subutex 2 mg resoribletter, sublinguale

indivior europe limited - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg

Subutex 8 mg resoribletter, sublinguale Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

subutex 8 mg resoribletter, sublinguale

indivior europe limited - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg

Paxlovid Den Europæiske Union - dansk - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Incivo Den Europæiske Union - dansk - EMA (European Medicines Agency)

incivo

janssen-cilag international n.v. - telaprevir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - incivo, i kombination med peginterferon alfa og ribavirin, er indiceret til behandling af genotype-1 kronisk hepatitis c hos voksne patienter med kompenseret leversygdom (herunder skrumpelever):der er i behandling naive;som tidligere er blevet behandlet med interferon alfa (pegyleret eller non-pegyleret) alene eller i kombination med ribavirin, herunder relapsers, delvis respondenter og respondenter null.